• KOL
    • atrial fibrillation
    • Stuart James Connolly

      Stuart James Connolly

      Hamilton Health Services, Hamilton, ON, Canada | Hamilton Health Sciences Hamilton, Ontario, Canada (S.J.C., S.Y., J.W.E.). | Hamilton Health Sciences Hamilton, Ontario, ...



      KOL Resume for Stuart James Connolly


      Hamilton Health Services, Hamilton, ON, Canada


      Population Health Research Institute, Hamilton, Ontario, Canada; Hamilton Health Sciences Centre, Hamilton, Ontario, Canada; Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

      Department of Medicine, McMaster University, Hamilton, ON, Canada (E.Z., J.N., L.X., J.W.E., M.C., S.J.C.).


      Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.

      Department of Medicine (Cardiology), McMaster University, Hamilton, ON, Canada

      Duke Clinical Research Institute, 200 Morris St, Durham, NC 27701

      Guy's and St Thomas’ Hospitals NHS Foundation Trust, London, United Kingdom


      Mc Master University, Hamilton, Canada

      Hamilton, Ontario


      Department of Cardiology, McMaster University, Hamilton, Ontario, Canada.

      Medicine (Cardiology), Population Health Rsch Institute and McMaster Univ, Hamilton, Canada

      Portola Pharmaceuticals, Inc., South San Francisco, CA, Certara, Menlo Park, CA, Portola Pharmaceticals, Inc., South San Francisco, CA, Seton Dell Medical School Stroke Institute, Austin, TX, McMaster University, Hamilton, ON



      Stuart James Connolly: Influence Statistics

      Sample of concepts for which Stuart James Connolly is among the top experts in the world.
      Concept World rank
      death acd ratio #1
      oral anticoagulation phase #1
      bolus andexanet #1
      aspirin design #1
      symptoms recurrent arrhythmias #1
      qtcfridericia placebo #1
      comparison ddd #1
      study 2500 patients #1
      camiat june #1
      amiodarone beta #1
      prevention shocks #1
      relationship scaf #1
      19603 patients #1
      antithrombins dabigatran #1
      benefit oral anticoagulation #1
      caop relative risk #1
      andexanet alfa usual #1
      diminishing proportional risk #1
      nonarrhythmic death year #1
      benzimidazoles dabigatran #1
      beta blockers prevention #1
      physiologic pacing caf #1
      dabigatran benzimidazoles dabigatran #1
      poor adherence placebo #1
      patients scaf progression #1
      dft betablocker #1
      nbugi aes #1
      azimilide 125 placebo #1
      permanent 6 months #1
      active amiodarone #1
      life dabigatran #1
      180 azimilide #1
      chads2 inr #1
      notesting #1
      celivarone groups placebo #1
      phase prescription tool #1
      notesting testing #1
      nonarrhythmic cardiac death #1
      sotalol betablocker #1
      dabigatran compared #1
      standard ddd vprm #1
      antiarrhythmic drug trials #1
      treatmentcontrol #1
      azimilide 125 #1
      ipsilateral plaque #1
      betrixaban 60 #1
      athena dronedarone #1
      azimilide placebo #1
      145±28 #1
      rivaroxaban riva #1


      Prominent publications by Stuart James Connolly

      KOL-Index: 24816

      BACKGROUND: In the Randomised Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial, dabigatran reduced occurrence of both stroke and haemorrhage compared with warfarin in patients who had atrial fibrillation and were at increased risk of stroke. We aimed to assess the effects of dabigatran compared with warfarin in the subgroup of patients with previous stroke or transient ischaemic attack.

      METHODS: In the RE-LY trial, 18,113 patients from 967 centres in 44 countries were ...

      Known for Transient Ischaemic Attack | Warfarin Patients | Previous Stroke | Dabigatran Compared | Atrial Fibrillation
      KOL-Index: 21877

      BACKGROUND: Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor.

      METHODS: In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of ...

      Known for Atrial Fibrillation | Year Warfarin | 150 Dabigatran | Rates Stroke | Systemic Embolism
      KOL-Index: 21450

      BACKGROUND: Coronary artery disease is a major cause of morbidity and mortality worldwide, and is a consequence of acute thrombotic events involving activation of platelets and coagulation proteins. Factor Xa inhibitors and aspirin each reduce thrombotic events but have not yet been tested in combination or against each other in patients with stable coronary artery disease.

      METHODS: In this multicentre, double-blind, randomised, placebo-controlled, outpatient trial, patients with stable ...

      Known for Coronary Artery | Rivaroxaban Aspirin | Major Bleeding | Myocardial Infarction | Combination Factor
      KOL-Index: 20808

      BACKGROUND: Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications.

      METHODS: This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous ...

      Known for Rivaroxaban Aspirin | Carotid Artery | Major Bleeding | Myocardial Infarction | Cardiovascular Death
      KOL-Index: 20808

      BACKGROUND: The Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial showed that dabigatran etexilate 150 mg BID was superior and dabigatran etexilate 110 mg BID was noninferior to warfarin in preventing stroke and systemic embolism in patients with atrial fibrillation. In this subgroup analysis, we assess the efficacy and safety of dabigatran in patients who did and did not receive concomitant antiplatelets.

      METHODS AND RESULTS: All comparisons used a Cox ...

      Known for Dabigatran Patients | Antiplatelet Therapy | Major Bleeding | Systemic Embolism | Randomized Evaluation
      KOL-Index: 19621

      BACKGROUND: The RE-LY trial (Randomized Evaluation of Long-Term Anticoagulant Therapy) compared dabigatran 150 and 110 mg twice daily with warfarin in 18 113 patients with atrial fibrillation. Those with prosthetic heart valves, significant mitral stenosis, and valvular heart disease (VHD) requiring intervention were excluded. Others with VHD were included.

      METHODS: This is a post hoc analysis of the RE-LY trial.

      RESULTS: There were 3950 patients with any VHD: 3101 had mitral ...

      Known for Warfarin Vhd | Atrial Fibrillation | Valvular Heart Disease | 95 Patients | Mitral Stenosis
      KOL-Index: 19366

      BACKGROUND: In the AVERROES study, apixaban, a novel factor Xa inhibitor, reduced the risk of stroke or systemic embolism in patients with atrial fibrillation who were at high risk of stroke but unsuitable for vitamin K antagonist therapy. We aimed to investigate whether the subgroup of patients with previous stroke or transient ischaemic attack (TIA) would show a greater benefit from apixaban compared with aspirin than would patients without previous cerebrovascular events.

      METHODS: In ...

      Known for Atrial Fibrillation | Patients Stroke | Apixaban Aspirin | Transient Ischaemic Attack | Systemic Embolism
      KOL-Index: 19245

      BACKGROUND: Many patients with atrial fibrillation are at high risk for stroke and require antithrombotic therapy. Antiarrhythmic drugs have not previously been shown to reduce the risk of stroke in atrial fibrillation. The effect of dronedarone, a new multichannel-blocking antiarrhythmic drug, on stroke has been evaluated in a randomized, double-blind clinical trial, ATHENA (A placebo-controlled, double-blind, parallel-arm Trial to assess the efficacy of dronedarone 400 mg BID for the ...

      Known for Cardiovascular Hospitalization | Dronedarone Patients | Stroke Atrial Fibrillation | Atrial Flutter | Antithrombotic Therapy
      KOL-Index: 19136

      BACKGROUND: Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke prevention in atrial fibrillation. The purpose of this study was to compare their risks of bleeding in the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial.

      METHODS AND RESULTS: The RE-LY trial randomized 18 113 patients to receive dabigatran 110 or 150 mg twice a day or warfarin dose adjusted to an international normalized ratio of 2.0 to 3.0 for a median follow-up of 2.0 years. ...

      Known for Warfarin Dabigatran | Atrial Fibrillation | Younger Patients | 2 Doses | Risk Major Bleeding
      KOL-Index: 18603

      BACKGROUND: Oral anticoagulation (OAC) therapy is effective in atrial fibrillation but requires vigilance to maintain the international normalized ratio in the therapeutic range. This report examines how differences in time in therapeutic range (TTR) between centers and between countries affect the outcomes of OAC therapy.

      METHODS AND RESULTS: In a posthoc analysis, the TTRs of patients on OAC in a randomized trial of OAC versus clopidogrel plus aspirin (Atrial Fibrillation Clopidogrel ...

      Known for Antiplatelet Therapy | Therapeutic Range | Atrial Fibrillation | International Normalized | Patients Oac
      KOL-Index: 18539

      BACKGROUND: Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients.

      METHODS: In a double-blind study, we randomly assigned 5599 patients with atrial fibrillation who were at increased risk for stroke and ...

      Known for Atrial Fibrillation | Apixaban Patients | Year Aspirin | Hazard Ratio | Risk Stroke
      KOL-Index: 18533

      BACKGROUND: Evidence suggests that physiologic pacing (dual-chamber or atrial) may be superior to single-chamber (ventricular) pacing because it is associated with lower risks of atrial fibrillation, stroke, and death. These benefits have not been evaluated in a large, randomized, controlled trial.

      METHODS: At 32 Canadian centers, patients without chronic atrial fibrillation who were scheduled for a first implantation of a pacemaker to treat symptomatic bradycardia were eligible for ...

      Known for Physiologic Pacing | Atrial Fibrillation Patients | Ventricular Pacemaker | Risk Stroke | Hospitalization Heart Failure
      KOL-Index: 18205

      BACKGROUND: Vitamin K antagonists reduce the risk of stroke in patients with atrial fibrillation but are considered unsuitable in many patients, who usually receive aspirin instead. We investigated the hypothesis that the addition of clopidogrel to aspirin would reduce the risk of vascular events in patients with atrial fibrillation.

      METHODS: A total of 7554 patients with atrial fibrillation who had an increased risk of stroke and for whom vitamin K-antagonist therapy was unsuitable were ...

      Known for Atrial Fibrillation | Clopidogrel Aspirin | Stroke Patients | Myocardial Infarction | Year Relative Risk
      KOL-Index: 18045

      BACKGROUND: Myocardial injury after non-cardiac surgery (MINS) increases the risk of cardiovascular events and deaths, which anticoagulation therapy could prevent. Dabigatran prevents perioperative venous thromboembolism, but whether this drug can prevent a broader range of vascular complications in patients with MINS is unknown. The MANAGE trial assessed the potential of dabigatran to prevent major vascular complications among such patients.

      METHODS: In this international, randomised, ...

      Known for Dabigatran Patients | Myocardial Injury | Cardiac Surgery | Mins Risk | Controlled Trial

      Key People For Atrial Fibrillation

      Top KOLs in the world
      Gregory Yoke Hong Lip
      atrial fibrillation heart failure stroke prevention
      John Camm MD John Camm
      atrial fibrillation myocardial infarction heart rate
      Emelia J Benjamin
      atrial fibrillation framingham heart study heart failure
      Harry J G M C Crijns
      atrial fibrillation heart failure sinus rhythm
      Isabelle C Van Gelder
      atrial fibrillation heart failure rate control
      Stefan Hans Hohnloser
      atrial fibrillation myocardial infarction sinus rhythm

      Stuart James Connolly:Expert Impact

      Concepts for whichStuart James Connollyhas direct influence:Atrial fibrillation,  Patients atrial fibrillation,  Heart failure,  Major bleeding,  Dabigatran warfarin,  Myocardial infarction,  Undetermined source,  Andexanet alfa.

      Stuart James Connolly:KOL impact

      Concepts related to the work of other authors for whichfor which Stuart James Connolly has influence:Atrial fibrillation,  Heart failure,  Oral anticoagulants,  Ischemic stroke,  Catheter ablation,  Major bleeding,  Myocardial infarction.



      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Hamilton Health Services, Hamilton, ON, Canada | Hamilton Health Sciences Hamilton, Ontario, Canada (S.J.C., S.Y., J.W.E.). | Hamilton Health Sciences Hamilton, Ontario, Canada. | Population Health Research Institute, Hamilton, Ontario, Canada; Divis

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.